Hulk Hogan, wrestling icon, dies at 71 in Florida home
LONDON - Aneurin Bevan University Health Board (ABUHB) in Wales has initiated a six-month pilot program for a new medical device known as Speedboat®, developed by Creo Medical (TASE:PMCN) Group plc (AIM: CREO), a company specializing in minimally invasive surgical endoscopy. ABUHB is the first in Wales to adopt this technology, which aims to improve the treatment of complex colorectal polyps.
The Speedboat® Submucosal Dissection (SSD) technology offers a less invasive alternative to traditional surgery, potentially enhancing patient outcomes and reducing recovery times. Traditional treatments for complex polyps typically involve multiple procedures or major surgery, both of which can lead to extended recovery periods and increased risks. The Speedboat® device allows for the effective removal of polyps in a single procedure, thus minimizing the need for further surgical intervention and facilitating quicker patient recovery.
Since the pilot’s inception before Christmas, three patients have been treated with the Speedboat® technology without any complications. These procedures were completed in one session, and the patients were discharged on the same day, with one patient resuming normal activities, including Christmas shopping, the following day.
The pilot, endorsed by ABUHB’s Clinical Safety and Effectiveness Group, is also supported by Creo’s clinical education program, which significantly shortens the training period for clinicians. This mentorship approach ensures that the new procedure is integrated quickly and safely while being cost-effective. It also presents a model for potential adoption by other health boards in Wales.
Finance Director & Innovation Executive Lead at ABUHB, Rob Holcombe, expressed pride in being the first to adopt this Welsh technology, emphasizing the pilot’s alignment with the Board’s commitment to enhancing patient care and mitigating the strain on surgical services. The pilot is part of ABUHB’s strategy to incorporate medical innovation through value-based health care outcome evaluation.
Creo’s CEO, Craig Gulliford, highlighted the significance of ABUHB using the Speedboat® technology, noting the potential benefits for patient outcomes and the possibility of reducing surgical waiting lists. Gulliford suggested that the success of the pilot could lead to broader adoption of the technology across Wales.
This report is based on a press release statement from Creo Medical Group plc.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.